Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth To Add “Consult a Doctor” For Cough/Cold Use By Children 2 To 6

This article was originally published in The Tan Sheet

Executive Summary

Wyeth Consumer Healthcare is re-labeling its OTC pediatric cough/cold medicines to advise caregivers to consult physicians before administering the products to 2- to 6-year-old children, the firm says in comments submitted to FDA Oct. 3

You may also be interested in...



Wyeth Replaces Dosing Measure For Pediatric Dimetapp, Robitussin Products

Wyeth Consumer Healthcare is voluntarily recalling and replacing Children's Dimetapp Cold & Chest Congestion and multiple products in its Robitussin line because the products' dosing cups are not marked with half-teaspoon units, the recommended dose for children ages 2 to 6, the firm said Oct. 29

Wyeth Replaces Dosing Measure For Pediatric Dimetapp, Robitussin Products

Wyeth Consumer Healthcare is voluntarily recalling and replacing Children's Dimetapp Cold & Chest Congestion and multiple products in its Robitussin line because the products' dosing cups are not marked with half-teaspoon units, the recommended dose for children ages 2 to 6, the firm said Oct. 29

Infant Cold Products Pulled; Waxman Looks For More OTC Risks

Manufacturers of OTC cough/cold medicines for children under 2 years old are voluntarily withdrawing the products from the market due to potential misuse, not from product safety concerns, the Consumer Healthcare Products Association said Oct. 11

Related Content

Topics

UsernamePublicRestriction

Register

PS101010

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel